Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE D46/EVOKE-03
2023-503501-11-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab monotherapy with Pembrolizumab + sacituzumab govitecan (2 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Planned start Oct 2023; status: authorised.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503501-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503501-11-00.